Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck pays €110mm up front for rights to AiCuris’s HCMV candidates

Executive Summary

AiCuris GMBH & Co. KG (antiviral and antibacterial drug development) has granted Merck & Co. Inc. exclusive worldwide rights to its pipeline of candidates for the treatment and prevention of human cytomegalovirus (HCMV) infection in bone marrow transplant patients, including lead compound letermovir (AIC246).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies